Indication

In adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.

Medicine details

Medicine name:
dapagliflozin (Forxiga)
SMC ID:
SMC2322
Pharmaceutical company
AstraZeneca UK Ltd
BNF chapter
Cardiovascular system
Submission type
Full
Publication due date:
12 April 2021
SMC meeting date:
02 March 2021
Patient group submission deadline:
01 February 2021